<qa>  What is the antisense oligonucleotide complementing to the RThis phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase RNR mRNA, in combination with capecitabine, in the setting of advancedmetastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma. 